Multi-ubiquitinated proteins are recognized by the 26S proteasome and degraded. This irreversible process has evolved into a central regulator of many different signaling pathways. The book is ...

Bortezomib, given intravenously, inhibits the 26S proteasome, and this activity has been shown to prevent the degradation of key anticancer proteins. The results of the Phase III APEX study ...